Epigenomics to Develop Remote Sample Tests to Identify People With Stage I Colorectal Cancer in 2008/2009
Posted on: Friday, 4 November 2005, 06:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c26917) has announced the addition of Cancer Diagnostics: Technology and Business Trends to their offering
Cancer Diagnostics: Technology and Business Trends examines the current status of in vivo imaging applications and in vitro cancer diagnostic tests, as well as their future potential as important screening tools.
Cancer diagnostic technologies and assays are essential for the detection, diagnosis, and management of cancer. For certain cancers, methods are available for screening apparently healthy (asymptomatic) average-risk individuals. In addition, some cancers, such as cervical and colorectal cancers, can be detected in an even earlier, precancerous stage of development. For example, remote sample tests being developed by Epigenomics in partnership with Roche promise to identify more people with Stage I colorectal cancer and could dramatically decrease the mortality associated with this disease. These tests may enter the market as early as 2008/2009.
The diverse applications in cancer screening, monitoring, and diagnostics require a broad range of tools. Cancer Diagnostics: Technology and Business Trends profiles selected companies competing in this market to develop such technologies and apply them in novel and innovative ways. Topics evaluated in this report include the following:
- New molecular imaging technologies, such as positron emission tomography (PET).
- Advances in in vitro diagnostic colorectal cancer screening.
- Efforts to identify novel cancer biomarkers and develop new pharmacodiagnostic cancer tests.
- The field of pharmacodiagnostics--the development of tests to predict response to therapy or to identify the optimal therapy for a patient. Two examples of pharmacodiagnostic tests that are already being used--the DakoCytomation EGFR PharmDx test, and Immunophenotyping of leukemia and lymphoma--are discussed.
- Potential opportunities for DNA methylation tests.
- Market opportunities for current tests and emerging applications.
Contents Include:
Executive Summary
Chapter 1. Background: Trends in Cancer Diagnostics
Chapter 2. Developments in Cancer Imaging
Chapter 3. Developments In Cancer In Vitro Diagnostics
Chapter 4. Business Outlook
Chapter 5. Expert Interviews
References
Glossary
Index
Tables & Figures
For more information visit http://www.researchandmarkets.com/reports/c26917
Source: Business Wire
Related Articles
- AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
- AMDL Inc. Introduces New Brand Name for Its DR-70 (FDP) In Vitro Diagnostic Cancer Test
- Decision by Medicare's CMS to Deny Coverage for 'Virtual' Colon Cancer Tests Underscores Lack of Evidence on Cancer Prevention
- Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
- DiaGenic Appoints SRL Ranbaxy Pathology Laboratories for Marketing Diagenic's Early Breast Cancer Test in India
- Understand Companion Diagnostics in Personalized Medicine and Cancer Therapy
- Luminous Award Winners Highlight the Importance of Genetic Testing and Pre-Screening for Potential Cancers
- Canada OKs Early Lung Cancer Test
- National Survey Reveals Americans Lack Understanding About Lung Cancer Testing Options
- Narrative Review: Screening for Colorectal Cancer in Patients With a First-Degree Relative With Colonic Neoplasia
 |
 |
User Comments (0)
RSS Feeds